Toll-like  ||| S:0 E:10 ||| JJ
receptor  ||| S:10 E:19 ||| NN
4  ||| S:19 E:21 ||| CD
( ||| S:21 E:22 ||| -LRB-
TLR4 ||| S:22 E:26 ||| NNP
)  ||| S:26 E:28 ||| -RRB-
gene  ||| S:28 E:33 ||| NN
polymorphisms  ||| S:33 E:47 ||| NN
in  ||| S:47 E:50 ||| IN
giant  ||| S:50 E:56 ||| JJ
cell  ||| S:56 E:61 ||| NN
arteritis  ||| S:61 E:71 ||| NN
To  ||| S:71 E:74 ||| TO
investigate  ||| S:74 E:86 ||| VB
potential  ||| S:86 E:96 ||| JJ
associations  ||| S:96 E:109 ||| NNS
between  ||| S:109 E:117 ||| IN
toll-like  ||| S:117 E:127 ||| JJ
receptor  ||| S:127 E:136 ||| NN
4  ||| S:136 E:138 ||| CD
( ||| S:138 E:139 ||| -LRB-
TLR4 ||| S:139 E:143 ||| NNP
)  ||| S:143 E:145 ||| -RRB-
gene  ||| S:145 E:150 ||| NN
polymorphisms  ||| S:150 E:164 ||| NNS
and  ||| S:164 E:168 ||| CC
susceptibility  ||| S:168 E:183 ||| JJ
to ||| S:183 E:185 ||| TO
,  ||| S:185 E:187 ||| ,
and  ||| S:187 E:191 ||| CC
clinical  ||| S:191 E:200 ||| JJ
features  ||| S:200 E:209 ||| NNS
of  ||| S:209 E:212 ||| IN
giant  ||| S:212 E:218 ||| JJ
cell  ||| S:218 E:223 ||| NN
arteritis  ||| S:223 E:233 ||| NNS
( ||| S:233 E:234 ||| -LRB-
GCA ||| S:234 E:237 ||| NNP
) ||| S:237 E:238 ||| -RRB-
.  ||| S:238 E:240 ||| .
A  ||| S:240 E:242 ||| DT
total  ||| S:242 E:248 ||| NN
of  ||| S:248 E:251 ||| IN
155  ||| S:251 E:255 ||| CD
patients  ||| S:255 E:264 ||| NNS
with  ||| S:264 E:269 ||| IN
biopsy-proven  ||| S:269 E:283 ||| JJ
GCA  ||| S:283 E:287 ||| NNS
who  ||| S:287 E:291 ||| WP
were  ||| S:291 E:296 ||| VBD
residents  ||| S:296 E:306 ||| NNS
of  ||| S:306 E:309 ||| IN
Reggio  ||| S:309 E:316 ||| NNP
Emilia ||| S:316 E:322 ||| NNP
,  ||| S:322 E:324 ||| ,
Italy ||| S:324 E:329 ||| NNP
,  ||| S:329 E:331 ||| ,
and  ||| S:331 E:335 ||| CC
210  ||| S:335 E:339 ||| CD
population-based  ||| S:339 E:356 ||| JJ
controls  ||| S:356 E:365 ||| NNS
from  ||| S:365 E:370 ||| IN
the  ||| S:370 E:374 ||| DT
same  ||| S:374 E:379 ||| JJ
geographical  ||| S:379 E:392 ||| JJ
area  ||| S:392 E:397 ||| NN
were  ||| S:397 E:402 ||| VBD
genotyped  ||| S:402 E:412 ||| VBN
for  ||| S:412 E:416 ||| IN
two  ||| S:416 E:420 ||| CD
coding  ||| S:420 E:427 ||| CD
single  ||| S:427 E:434 ||| JJ
nucleotide  ||| S:434 E:445 ||| JJ
polymorphisms  ||| S:445 E:459 ||| NN
of  ||| S:459 E:462 ||| IN
TLR4  ||| S:462 E:467 ||| NNP
( ||| S:467 E:468 ||| -LRB-
Asp299Gly  ||| S:468 E:478 ||| NNP
and  ||| S:478 E:482 ||| CC
Thr399Ile ||| S:482 E:491 ||| CD
)  ||| S:491 E:493 ||| -RRB-
by  ||| S:493 E:496 ||| IN
molecular  ||| S:496 E:506 ||| JJ
methods ||| S:506 E:513 ||| NNS
.  ||| S:513 E:515 ||| .
The  ||| S:515 E:519 ||| DT
patients  ||| S:519 E:528 ||| NNS
were  ||| S:528 E:533 ||| VBD
subgrouped  ||| S:533 E:544 ||| VBN
according  ||| S:544 E:554 ||| VBG
to  ||| S:554 E:557 ||| TO
the  ||| S:557 E:561 ||| DT
presence  ||| S:561 E:570 ||| NN
or  ||| S:570 E:573 ||| CC
absence  ||| S:573 E:581 ||| NN
of  ||| S:581 E:584 ||| IN
polymyalgia  ||| S:584 E:596 ||| JJ
rheumatica  ||| S:596 E:607 ||| NN
and  ||| S:607 E:611 ||| CC
severe  ||| S:611 E:618 ||| JJ
ischemic  ||| S:618 E:627 ||| JJ
complications  ||| S:627 E:641 ||| NNS
( ||| S:641 E:642 ||| -LRB-
visual  ||| S:642 E:649 ||| JJ
loss  ||| S:649 E:654 ||| NN
and ||| S:654 E:657 ||| CC
/ ||| S:657 E:658 ||| NNP
or  ||| S:658 E:661 ||| CC
cerebrovascular  ||| S:661 E:677 ||| JJ
accidents ||| S:677 E:686 ||| NNS
) ||| S:686 E:687 ||| -RRB-
.  ||| S:687 E:689 ||| .
The  ||| S:689 E:693 ||| DT
distribution  ||| S:693 E:706 ||| NN
of  ||| S:706 E:709 ||| IN
allele  ||| S:709 E:716 ||| NN
and  ||| S:716 E:720 ||| CC
genotype  ||| S:720 E:729 ||| JJ
frequencies  ||| S:729 E:741 ||| NN
did  ||| S:741 E:745 ||| VBD
not  ||| S:745 E:749 ||| RB
differ  ||| S:749 E:756 ||| VBP
significantly  ||| S:756 E:770 ||| RB
between  ||| S:770 E:778 ||| IN
GCA  ||| S:778 E:782 ||| NNP
patients  ||| S:782 E:791 ||| NNS
and  ||| S:791 E:795 ||| CC
healthy  ||| S:795 E:803 ||| JJ
controls ||| S:803 E:811 ||| NNS
.  ||| S:811 E:813 ||| .
Carriers  ||| S:813 E:822 ||| NNS
of  ||| S:822 E:825 ||| IN
the  ||| S:825 E:829 ||| DT
-299  ||| S:829 E:834 ||| NNP
G  ||| S:834 E:836 ||| NNP
allele  ||| S:836 E:843 ||| NNS
( ||| S:843 E:844 ||| -LRB-
G ||| S:844 E:845 ||| NNP
/ ||| S:845 E:846 ||| NNP
A+  ||| S:846 E:849 ||| NNP
G ||| S:849 E:850 ||| NNP
/ ||| S:850 E:851 ||| NNP
G ||| S:851 E:852 ||| NNP
)  ||| S:852 E:854 ||| -RRB-
[ ||| S:854 E:855 ||| -LRB-
odds  ||| S:855 E:860 ||| JJ
ratio  ||| S:860 E:866 ||| NN
( ||| S:866 E:867 ||| -LRB-
OR ||| S:867 E:869 ||| NNP
)  ||| S:869 E:871 ||| -RRB-
1.78 ||| S:871 E:875 ||| CD
,  ||| S:875 E:877 ||| ,
95 ||| S:877 E:879 ||| CD
%  ||| S:879 E:881 ||| NN
confidence  ||| S:881 E:892 ||| NN
intervals  ||| S:892 E:902 ||| NNS
( ||| S:902 E:903 ||| -LRB-
CI ||| S:903 E:905 ||| NNP
)  ||| S:905 E:907 ||| -RRB-
0.90-3.50 ||| S:907 E:916 ||| CD
) ||| S:916 E:917 ||| -RRB-
]  ||| S:917 E:919 ||| -RRB-
were  ||| S:919 E:924 ||| VBD
more  ||| S:924 E:929 ||| RBR
frequent  ||| S:929 E:938 ||| JJ
among  ||| S:938 E:944 ||| IN
GCA  ||| S:944 E:948 ||| NNP
patients  ||| S:948 E:957 ||| NNS
than  ||| S:957 E:962 ||| IN
among  ||| S:962 E:968 ||| IN
the  ||| S:968 E:972 ||| DT
controls ||| S:972 E:980 ||| NNS
,  ||| S:980 E:982 ||| ,
but  ||| S:982 E:986 ||| CC
the  ||| S:986 E:990 ||| DT
difference  ||| S:990 E:1001 ||| NN
was  ||| S:1001 E:1005 ||| VBD
not  ||| S:1005 E:1009 ||| RB
statistically  ||| S:1009 E:1023 ||| RB
significant ||| S:1023 E:1034 ||| JJ
.  ||| S:1034 E:1036 ||| .
No  ||| S:1036 E:1039 ||| DT
significant  ||| S:1039 E:1051 ||| JJ
associations  ||| S:1051 E:1064 ||| NNS
were  ||| S:1064 E:1069 ||| VBD
found  ||| S:1069 E:1075 ||| VBN
when  ||| S:1075 E:1080 ||| WRB
GCA  ||| S:1080 E:1084 ||| NNP
patients  ||| S:1084 E:1093 ||| NNS
with  ||| S:1093 E:1098 ||| IN
and  ||| S:1098 E:1102 ||| CC
without  ||| S:1102 E:1110 ||| IN
PMR  ||| S:1110 E:1114 ||| NNP
or  ||| S:1114 E:1117 ||| CC
with  ||| S:1117 E:1122 ||| IN
and  ||| S:1122 E:1126 ||| CC
without  ||| S:1126 E:1134 ||| IN
severe  ||| S:1134 E:1141 ||| JJ
ischemic  ||| S:1141 E:1150 ||| JJ
complications  ||| S:1150 E:1164 ||| NNS
were  ||| S:1164 E:1169 ||| VBD
compared ||| S:1169 E:1177 ||| VBN
.  ||| S:1177 E:1179 ||| .
Our  ||| S:1179 E:1183 ||| PRP$
data  ||| S:1183 E:1188 ||| NNS
suggest  ||| S:1188 E:1196 ||| VBP
that  ||| S:1196 E:1201 ||| IN
the  ||| S:1201 E:1205 ||| DT
TLR4  ||| S:1205 E:1210 ||| JJ
gene  ||| S:1210 E:1215 ||| NN
polymorphisms  ||| S:1215 E:1229 ||| NNS
are  ||| S:1229 E:1233 ||| VBP
not  ||| S:1233 E:1237 ||| RB
associated  ||| S:1237 E:1248 ||| VBN
with  ||| S:1248 E:1253 ||| IN
susceptibility  ||| S:1253 E:1268 ||| VBG
to ||| S:1268 E:1270 ||| TO
,  ||| S:1270 E:1272 ||| ,
and  ||| S:1272 E:1276 ||| CC
clinical  ||| S:1276 E:1285 ||| JJ
expression  ||| S:1285 E:1296 ||| NN
of ||| S:1296 E:1298 ||| IN
,  ||| S:1298 E:1300 ||| ,
GCA  ||| S:1300 E:1304 ||| NNP
in  ||| S:1304 E:1307 ||| IN
Italian  ||| S:1307 E:1315 ||| JJ
patients ||| S:1315 E:1323 ||| NNS
.  ||| S:1323 E:1325 ||| .
